Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488313 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
A Phase 2 study of Ornithine Transcarbamylase Deficiency and OTC Deficiency, sponsored by Arcturus Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT06488313 is a Phase 2 study of Ornithine Transcarbamylase Deficiency and OTC Deficiency that is actively recruiting participants, run by Arcturus Therapeutics. The registered enrollment target is 9 participants, below the 65-participant average among 4 other Ornithine Transcarbamylase Deficiency trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06488313, a Phase 2 study of Ornithine Transcarbamylase Deficiency and OTC Deficiency, is actively recruiting participants, sponsored by Arcturus Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.
Conditions Studied
Interventions
- BIOLOGICAL ARCT-810
Study Locations (1)
Maryland
- Uncommon Cures - Chevy Chase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06488313
The ClinicalTrials.gov registry entry for NCT06488313 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 4 other Ornithine Transcarbamylase Deficiency trials with a reported enrollment target (86% lower). The listed sponsor is Arcturus Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ornithine Transcarbamylase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which ARCT-810 is the first listed.
NCT06488313 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06488313 about?
NCT06488313 is a clinical study titled "A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD". Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.
What is the current status of trial NCT06488313?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2024-11-04. Estimated completion is 2026-09-01.
What conditions does trial NCT06488313 study?
This clinical trial studies the following conditions: Ornithine Transcarbamylase Deficiency, OTC Deficiency, OTCD.
What interventions are being tested in trial NCT06488313?
The interventions under investigation include: ARCT-810 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06488313?
This trial is sponsored by Arcturus Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06488313 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ornithine Transcarbamylase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liver Disease in Urea Cycle Disorders
RECRUITING
-
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
RECRUITING · Phase 1
-
Hepatic Histopathology in Urea Cycle Disorders
RECRUITING
-
A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.